- Home
- CRON vs AVBP Comparison
CRON vs AVBP Comparison
Compare CRON & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRON
- AVBP
- Stock Information
- Founded
- CRON 2012
- AVBP 2021
- Country
- CRON Canada
- AVBP United States
- Employees
- CRON N/A
- AVBP N/A
- Industry
- CRON Medicinal Chemicals and Botanical Products
- AVBP
- Sector
- CRON Health Care
- AVBP
- Exchange
- CRON Nasdaq
- AVBP NYSE
- Market Cap
- CRON 707.7M
- AVBP 617.4M
- IPO Year
- CRON N/A
- AVBP 2024
- Fundamental
- Price
- CRON $1.79
- AVBP $17.96
- Analyst Decision
- CRON Hold
- AVBP Strong Buy
- Analyst Count
- CRON 2
- AVBP 6
- Target Price
- CRON $3.00
- AVBP $39.00
- AVG Volume (30 Days)
- CRON 1.4M
- AVBP 191.8K
- Earning Date
- CRON 05-08-2025
- AVBP 03-03-2025
- Dividend Yield
- CRON N/A
- AVBP N/A
- EPS Growth
- CRON N/A
- AVBP N/A
- EPS
- CRON 0.11
- AVBP N/A
- Revenue
- CRON $117,615,000.00
- AVBP N/A
- Revenue This Year
- CRON $22.27
- AVBP $63.13
- Revenue Next Year
- CRON $7.36
- AVBP N/A
- P/E Ratio
- CRON $16.68
- AVBP N/A
- Revenue Growth
- CRON 34.82
- AVBP N/A
- 52 Week Low
- CRON $1.77
- AVBP $14.35
- 52 Week High
- CRON $3.14
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- CRON 35.67
- AVBP 27.89
- Support Level
- CRON $1.78
- AVBP $17.89
- Resistance Level
- CRON $1.84
- AVBP $19.04
- Average True Range (ATR)
- CRON 0.06
- AVBP 1.00
- MACD
- CRON -0.01
- AVBP -0.04
- Stochastic Oscillator
- CRON 4.55
- AVBP 5.56
About CRON Cronos Group Inc. Common Share
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.